MoonLake Immunotherapeutics - Ordinary Shares - Class A
MLTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.01B
Close$
$4.01
66.1% downside
Current Fair Value
66.1% downsideOvervalued by 66.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.01 Billion |
|---|---|
| Enterprise Value | $632.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.53 |
| Beta | 1.08 |
| Outstanding Shares | 73,915,296 |
Return
| Return on Equity | -61.75% |
|---|---|
| Return on Assets | -46.07% |
| Return on Invested Capital | -35.92% |
Valuation & Multiples
| P/E Ratio | -3.08 |
|---|---|
| PEG | -25.81 |
| Price to Sales | - |
| Price to Book Ratio | 2.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.33 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.77
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3750▲ 12.51% |
|---|---|
| Total Calls | 1,431,100▼ 8.86% |
| Total Puts | 536,700▲ 36.77% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 102.76%▲ 14.30% |
|---|---|
| Total Invested | $1.43B▲ 21.58% |
| Investors Holding | 187▲ 28.00% |
ESG Score
No data